KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF STAPOKIBART INJECTION FOR THE TREATMENT OF SEASONAL ALLERGIC RHINITIS ACCEPTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL TRIAL OF STAPOKIBART INJECTION FOR THE TREATMENT OF SEASONAL ALLERGIC RHINITIS ACHIEVED PRIMARY ENDPOINTS
KEYMED BIO-B: Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
KEYMED BIO-B: Notification Letter to Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
KEYMED BIO-B: FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING
KEYMED BIO-B: NOTICE OF ANNUAL GENERAL MEETING
KEYMED BIO-B: (1) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) AMENDMENTS TO THE ARTICLES OF ASSOCIATION; (4) RE-APPOINTMENT OF AUDITOR; AND (5) NOTICE OF ANNUAL GENERAL MEETING
KEYMED BIO-B: 2023 ANNUAL REPORT
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT UPDATE ON THE LICENSE AGREEMENT WITH ASTRAZENECA ON CMG901 (AZD0901)
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
KEYMED BIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY
KEYMED BIO-B: DATE OF BOARD MEETING
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT SHARE PURCHASE PURSUANT TO THE 2022 RESTRICTED SHARE UNIT SCHEME
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL TRIAL OF CM310 FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPS ACHIEVED PRIMARY ENDPOINTS
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF STAPOKIBART FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN ADULTS ACCEPTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
No Data